Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease

Respiratory Physiology and Neurobiology

Volumn 196, Issue 1, 2014, Pages 1-7

  Mahler, Donald A ^a   Gifford, Alex H ^a   Gilani, Aamir ^a   Waterman, Laurie A ^b   Hilton, Jennifer ^b   Chang, Andrew S ^a   Kupchak, Brian R ^c   Kraemer, William J ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Aprepitant; Beta endorphin; Chronic obstructive pulmonary disease; Resistive load breathing; Substance P

Indexed keywords

APREPITANT; BETA ENDORPHIN; NALOXONE; NEUROKININ 1 RECEPTOR; PLACEBO; SUBSTANCE P; MORPHOLINE DERIVATIVE; NARCOTIC ANTAGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DYSPNEA; FEMALE; HUMAN; MALE; PERCEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTIVE LOAD BREATHING; RESPIRATION CONTROL; RESPIRATION LOAD; SIGNAL TRANSDUCTION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BREATHING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

AGED; BETA-ENDORPHIN; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HUMANS; MALE; MORPHOLINES; NALOXONE; NARCOTIC ANTAGONISTS; NEUROKININ-1 RECEPTOR ANTAGONISTS; PERCEPTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; SUBSTANCE P; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896085784     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.02.008     Document Type: Article

References (34)

1. Arai H., Emson P.C. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 1986, 399:240-249.
2. Avrameas S. Amplification systems in immunoenzymatic techniques. J. Immunol. Methods 1992, 150:23-32.
3. Bellofiore S., Di Maria G.U., Privitera S., Sapienza S., Milic-Emili J., Mistretta A. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am. Rev. Respir. Dis. 1990, 142:812-816.
4. Bonham A.C. Neurotransmitters in the CNS control of breathing. Respir. Physiol. 1995, 101:219-230.
5. Curran M.P., Robinson D.M. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009, 69:1853-1878.
6. De Swert K.O., Joos G.F. Extending the understanding of sensory neuropeptides. Eur. J. Pharmacol. 2006, 533:171-181.
7. Doi A., Ramirez J.M. Neuromodulation and the orchestration of the respiratory rhythm. Respir. Physiol. Neurobiol. 2008, 164:96-104.
8. Duggan A.W., Hendry I.A., Morton C.R., Hutchison W.D., Zhao Z.Q. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res. 1988, 451:261-273.
9. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
10. Gaensler E.A., Smith A.A. Attachment for automated single breath diffusing capacity measurement. Chest 1973, 63:136-145.
11. Gifford A.H., Mahler D.A., Waterman L.A., Ward J., Kraemer W.J., Kupchak B.R., Baird J.C. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD 2011, 8:160-166.
12. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 1999, 159:179-187.
13. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry 2002, 63(Suppl. 11):18-24.
14. Hughes J., Kosterlitz H.W., Smith T.W. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br. J. Pharmacol. 1997, 120:428-436. (discussion 426-427).
15. Kraemer W.J., Patton J.F., Knuttgen H.G., Marchitelli L.J., Cruthirds C., Damokosh A., Harman E., Frykman P., Dziados J.E. Hypothalamic-pituitary-adrenal responses to short-duration high-intensity cycle exercise. J. Appl. Physiol. 1989, 66:161-166.
16. Kudlacz E.M., Logan D.E., Shatzer S.A., Farrell A.M., Baugh L.E. Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by NK1 and NK2 receptor antagonists. Eur. J. Pharmacol. 1993, 241:17-25.
17. Macintyre N., Crapo R.O., Viegi G., Johnson D.C., van der Grinten C.P., Brusasco V., Burgos F., Casaburi R., Coates A., Enright P., Gustafsson P., Hankinson J., Jensen R., McKay R., Miller M.R., Navajas D., Pedersen O.F., Pellegrino R., Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005, 26:720-735.
18. Mahler D.A., Murray J.A., Waterman L.A., Ward J., Kraemer W.J., Zhang X., Baird J.C. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur. Respir. J. 2009, 33:771-777.
19. Mahler D.A., Waterman L.A., Ward J., McCusker C., ZuWallack R., Baird J.C. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007, 132:1283-1290.
20. 3H]SP as the radioligand. Brain Res. 1984, 307:147-165.
21. Meek P.M., Banzett R., Parshall M.B., Gracely R.H., Schwartzstein R.M., Lansing R. Reliability and validity of the multidimensional dyspnea profile. Chest 2012, 141:1546-1553.
22. Mellen N.M., Janczewski W.A., Bocchiaro C.M., Feldman J.L. Opioid-induced quantal slowing reveals dual networks for respiratory rhythm generation. Neuron 2003, 37:821-826.
23. Parshall, M.B., Schwartzstein, R.M., Adams, L., Banzett, R.B., Manning, H.L., Bourbeau, J., Calverley, P.M., Gift, A.G., Harver, A., Lareau, S.C., Mahler, D.A., Meek, P.M., O'Donnell, D.E., on behalf of the ATS Committee on Dyspnea, 2012. An Official American Thoracic Society Statement: update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 185, 435-452.
24. Pepin V., Saey D., Whittom F., LeBlanc P., Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005, 172:1517-1522.
25. Porstmann T., Kiessig S.T. Enzyme immunoassay techniques. An overview. J. Immunol. Methods 1992, 150:5-21.
26. Quartara L., Maggi C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998, 32:1-49.
27. Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., Zielinski, J., Global Initiative for Chronic Obstructive Lung Disease, 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532-555.
28. Ribeiro-da-Silva A., Hokfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 2000, 34:256-271.
29. Schaible H.G., Jarrott B., Hope P.J., Duggan A.W. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes. Brain Res. 1990, 529:214-223.
30. Solway J., Leff A.R. Sensory neuropeptides and airway function. J. Appl. Physiol. 1991, 71:2077-2087.
31. Stein C., Lang L.J. Peripheral mechanisms of opioid analgesia. Curr. Opin. Pharmacol. 2009, 9:3-8.
32. Tomaki M., Ichinose M., Miura M., Hirayama Y., Yamauchi H., Nakajima N., Shirato K. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 1995, 151:613-617.
33. Zebraski S.E., Kochenash S.M., Raffa R.B. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000, 66:2221-2231.
34. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.